We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Fatty Acid Levels Could Help Predict Psychosis Risk

By HospiMedica International staff writers
Posted on 03 Nov 2016
A novel probabilistic model that combines history, clinical assessment, and fatty-acid biomarkers could help predict transition to first-episode psychosis, claims a new study.

Researchers at the University of Adelaide (UA; Australia), the Medical University of Vienna (Austria), and other institutions conducted a study in 40 patients in Austria to explore if a probabilistic model that combine medical historical, clinical risk factors, oxidative stress and cell membrane fatty acids biomarkers, and resting quantitative electroencephalography (qEEG), could improve the identification of patients with ultra-high risk (UHR) of psychosis.

The researchers then analyzed concurrent and baseline data of the study cohort, who overall exhibited a 28% one-year transition rate to psychosis. More...
They then clustered several significant variables into historical (history of drug use), clinical (Positive and Negative Symptoms Scale [PNSS] and Global Assessment of Function [GAF] scores), and biomarker (total omega-3, nervonic acid) groups, and calculated the post-test probability of transition for each group separately and for group combinations, using the odds ratio form of Bayes’ rule.

The results showed that the combination of all three variable groups vastly improved the specificity of prediction. The model identified over 70% of UHR patients who transitioned within one year, compared with 28% identified by standard UHR criteria. The model classified 77% of cases as very high or low risk based on history and clinical assessment, suggesting that a staged approach, which reserved fatty-acid markers for 23% of cases remaining at intermediate probability following bedside interview, could be the most efficient. The study was published on September 20, 2016, in the Translational Psychiatry.

“Currently, all patients in the ultra-high risk group are considered to have a similar chance of a future psychotic episode; however, we have been able to identify high, intermediate and low-risk groups. The model may help clinicians to decide when a patient's risk of psychosis outweighs any side effects of treatment,” said lead author psychiatrist Scott Clark, MD, of the University of Adelaide. “Fatty acids such as omega-3 and nervonic acid are critical for the normal functioning of the brain, and low levels have been associated with the development of psychosis in high-risk groups.”

The concept of clinical UHR for psychosis was developed to facilitate early detection and intervention, and is defined by a cluster of subthreshold psychotic symptoms. These can include perceptions, such as hallucinations; thinking - for example, ideas of reference, odd beliefs, or magical thinking; and trait risk factors like a family history of psychosis. These are accompanied by impairment in day-to-day function. In recent meta-analysis, studies show that less than 30% of UHR patients will have transitioned to psychosis three years after identification.

Related Links:
University of Adelaide
Medical University of Vienna

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Hypodermic Syringe
SurTract™ Safety Syringe
Patient Preoperative Skin Preparation
BD ChloraPrep
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image Credit: MedUni Wien/Houdek

New Surgical Technique Enlarges Aortic Root for Larger Valve Implantation

When replacing a diseased aortic valve, a small aortic root can prevent surgeons from implanting a prosthesis large enough for the patient’s body size. This can lead to patient-prosthesis mismatch, causing... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Medical Imaging

view channel
Image: Brain PET imaging could help identify Alzheimer’s patients most likely to benefit from available therapies (Image Credit: iStock)

Amyloid and Tau PET Guide Selection and Monitoring of Alzheimer’s Therapy

Alzheimer’s disease is the most common form of dementia and can be difficult to distinguish from other causes of cognitive decline. According to the World Health Organization (WHO), 57 million people were... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.